

**Freedom of Information Act 2000 - Request Reference Fol/21/093**  
**Anti-VEFG Treatments for Eye Conditions**

**Request Details**

I am analysing the usage of anti-VEFG treatments for eye conditions. I would greatly appreciate if you could answer three questions:

**1. For the 4-month period from September to December 2020, how many patients has your trust treated with the following anti-VEGF treatments:**

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Fluocinolone acetonide
- Ranibizumab

**2. Within your trust how many intra-vitreous injections/implants of each of the following treatments have been used in the four-month period from September to December 2020:**

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Fluocinolone
- Ranibizumab

**3. If your trust is able to identify intra-vitreous injections/implants by eye condition, please provide the number of injections/implants used in the four-month period from September to December 2020 for each of the following conditions:**

**Wet Age Related Macular Degeneration (wAMD)**

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Ranibizumab

**Diabetic Macular Oedema (DMO)**

- Aflibercept
- Bevacizumab
- Dexamethasone
- Ranibizumab

**Retinal Vein Occlusion - Central (CRVO) or Branch (BRVO)**

- Aflibercept
- Bevacizumab

- **Dexamethasone**
- **Ranibizumab**

## **Response Details**

In completing a search for the information requested, Cardiff and Vale University Health Board (the UHB) has confirmed that this information is not centrally recorded or collated. To retrieve the information requested would require a manual search through individual records and the UHB considers that this would exceed the limit set within regulations for responding to a request. The UHB has therefore relied upon the Section 12 exemption ('Exemption where cost of compliance exceeds appropriate limit') of the Freedom of Information Act 2000 and is refusing your request.

The UHB has estimated that to complete the work needed to respond to this request would exceed the time limit as set within regulations to respond to a Freedom of Information Act request. Under the Act there is an allowance of two and a half days, or 18 hours, to comply with a request and the cost limit set within the fees regulations for this amount of work (18 hours) is £450 for the UHB. The fees regulations specify that the cost of complying with a request must be calculated at the rate of £25 per hour.

To comply with our Section 16 obligation, the duty to provide advice and assistance, the UHB can advise that in respect of question 2 the majority are issued directly to the department/clinic and not as named patient supplies.

Below is the data in respect of the supplies issued to the departments/clinics:

- Afibercept 1031
- Bevacizumab 36
- Brolucizumab 0
- Dexamethasone 42
- Fluocinolone 0
- Ranibizumab 1184